Aphios Corporation

Other

Louisiana State University and Agricultural & Mechanical College

Arphios Corporation

Trevor Percival Castor

Glenn T Hong

Jonathan Steven Alexander

Theodore A Tyler

Geoffrey Purdum

Maury D Cosman

Peter Richard d'Entremont

Arthur D Lander

J David Rios

Lisa M Schrott

April C Carpenter

Lisa Bastiani Lallos

Maria I Vizcaino

James A McSwiggen

Ling Chu

Christopher Shallice

Hemant M Chikarmane

Michael Richard Pelletier

Petr O Ilynskii

Vasudevacharya Jayarama

Petr O Ilyinskii

Richard Joseph Student

Matthew Albert Britz

This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

Room temperature stable, single shot mRNA vaccine for COVID-19

This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana () and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating thebiomass to convert carboxylic acids prior to extraction and purification. Alternatively, and preferably because of manufacturing cost and product stability, the carboxylic acids can be first extracted and purified. They can be utilized in the carboxylic acid form or stored in a stable manner until converted to cannabinoids for use in medicine. This invention provides an efficient method for their conversion utilizing a high-pressure reactor under inert conditions.

Thermal conversion of CBDA and other carboxylic cannabinoids

The present invention pertains to the nanoencapsulation of siRNA and other biologics in phospholipid nanosomes for the improved delivery of siRNA and other biologics to targeted diseased human or animal organs and human or animal cells and apparatus and methods for making the same. In embodiments of the present invention, novel siRNAs were designed to down regulate CCR5 and CD4, based on an analysis of all known alternative transcripts for each gene from both human and monkey () genomes. Embodiments of the present invention feature supercritical, critical and near critical fluids. Embodiments of the present invention also pertain to down regulation of CXCR4 receptor and targeting of nanosomes containing specific siRNA sequences to cells expressing those receptors on the cell surface by coating them with specific ligands. These include ligands for the receptors CCR5, CD4 and CXCR4.

CCR5 and CD4 siRNA-targeted phospholipid nanosomes therapeutics for treatment of HIV-1 and other diseases

Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Bryoid compositions, methods of making and use thereof

Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Combination HIV therapeutic

Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.

Combination therapeutics and methods for the treatment of neurodegenerative and other diseases

Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.

Transplantation therapies

Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease.

Drug delivery system and method for the treatment of neuro-degenerative disease

This invention is for formulations of analogs of the non-toxic and inert Vitamin D3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, Vitamin D deficiency, autoimmune disease such as Multiple Sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert Vitamin D3 and the non-toxic and mostly inert Vitamin D3 pre-hormone.

Formulations and compositions of vitamin D analogs for treating and preventing cancer and other diseases

Embodiments of the present invention are directed to an apparatus and methods for making nucleic acid loaded nanosomes. One embodiment of the present invention directed to an apparatus comprises a first containment means for containing a mixture of an aqueous solution of nucleic acid and a phospholipid solution with a supercritical, critical or near critical fluid. The apparatus further comprises injection means in fluid communication with said first containment means for receiving the mixture and releasing the mixture as a stream into a decompression liquid. The apparatus further comprises a decompression vessel in fluid communication with the injection means for holding a decompression liquid and receiving the mixture as a stream. The stream forms one or more nanosomes loaded with a nucleic acid in the decompression liquid.

Apparatus and methods for making nanosomes loaded with nucleic acid

Embodiments of the present invention are directed to articles of manufacture, spheres having a diameter of 50 to 500 nanometers which contain poorly soluble drugs and methods of making such spheres. Embodiments of the present invention have particular application for the following drug candidates and closely related poorly soluble derivatives of such candidates: (i) indole hydrazinecarbothioamide [NSC 73306]; (ii) fenretinide (4HPR) [NSC 374551]; (iii) safingol [NSC 714503]; (iv) 17-allylamino demethoxygeldanamycin (17-AAG) [NSC 330507]; and (v) an aminoflavone drug [NSC 686288].

Growing community of inventors

Arlington, MA, United States of America

Trevor Percival Castor